ImmunityBio Reports 15-Month Durable Complete Response with Chemotherapy-Free CD19 CAR-NK Therapy in Waldenström Lymphoma

Recently (January 16, 2026),ImmunityBio Updates Ongoing Clinical Study of its CD19 CAR-NK CellsEfficacy and Safety Data of QUILT-106, Reported in the Context of No Chemotherapy RequiredWaldenström's Macroglobulinemia(Waldenstrom Lymphoma)PatientAchieved a complete remission lasting 15 months.

On the day the news was released,ImmunityBio's stock price surged 39.75%.

ImmunityBio has designed an allogeneic CD19 CAR-NK cell and is currently conducting a clinical study.QUILT-106（NCT06334991), to evaluate withRituximab(rituximab)Combination TherapyEfficacy and Safety of Waldenström's Macroglobulinemia. The study has enrolled 4 patients, all of whom received outpatient treatment.

The First Two Patients in the StudyNot meeting the standard treatment criteria, and inOutpatient EnvironmentReceived a total of 8 doses of CAR-NK cell therapy in China, andNo need for chemotherapy pre-treatment. The specific solution is CD19 CAR-NK andIn combination with rituximab, administered twice every 21 days as one cycle, for a total of 4 cycles (8 doses of CAR-NK + 6 doses of rituximab), and no other treatments were conducted thereafter. Effectiveness was evaluated after two cycles of treatment.

Image Source: Reference 1

August 2025,ImmunityBio Reports Data on First Two Patients: One WM Patient Treated with CD19 CAR-NK Monotherapy Achieves Complete Response in Third-Line Treatment, and Another Patient Receives CD19 CAR-NK Plus Rituximab Combination Therapy, Achieving Complete Response Maintained at 6-Month Follow-Up.

Data updated on January 16, 2026, shows,The complete responses in the first two patients are still ongoing,They were maintained for 7 months and 15 months, respectively. Additionally, among all 4 enrolled patients,The observed disease control rate was 100%.。

It is worth noting that,The treatment regimen of CD19 CAR-NK combined with rituximab not only offers durable remission,Its response speed is also very fast.——According to the report, only two cycles (4 dosesCAR-NK) later, complete remission was achieved.

Currently,Recruitment and follow-up for the QUILT-106 study are ongoing, and more clinical updates will be provided as additional patients achieve accurate and durable remission. In addition,ImmunityBio is designing a follow-up study to evaluateCD19 CAR-NK+Anktiva (IL-15 Superagonist) +Rituximab TreatmentIndolent lymphoma.

In fact, compared with traditional CAR-T therapy,ImmunityBio's CD19 CAR-NK is an off-the-shelf product designed for outpatient administration, eliminating the need for chemotherapy-based lymphodepletion, further addressing the limitations of traditional CAR-T cell therapy.

However, the persistence issue of CAR-NK has always been a significant factor limiting its development.ImmunityBio's CAR-NK Demonstrates Complete Remission for Up to 15 Months, Showing Promising Prospects.

In addition,ImmunityBio is also doing well.

In September 2024, ImmunityBio, a company founded by "the world's richest doctor" Patrick Soon-Shiong, found itself in a financial predicament, partly due to its IL-15 superagonist.Anktiva's Sales Encounter Setbacks, Partly Due to Ongoing Research Investment.

But in 2025,Anktiva's sales rapidly increased, with net product revenue for the year reaching approximately $113 million.A year-on-year surge of approximately 700%, coupled with the promising prospects shown by the CAR-NK pipeline,ImmunityBio's stock price begins to rebound.

References:

1.https://www.businesswire.com/news/home/20260116046721/en/ImmunityBio-Announces-Durable-Complete-Response-of-15-Months-with-a-Chemotherapy-Free-CD19-CAR-NK-Cell-Therapy-in-Waldenstrom-Lymphoma